Back to top
more

National Vision (EYE)

(Delayed Data from NSDQ)

$13.20 USD

13.20
1,140,149

-0.38 (-2.80%)

Updated Aug 2, 2024 04:00 PM ET

After-Market: $13.20 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (101 out of 251)

Industry: Medical - Products

Better trading starts here.

Zacks News

National Vision (EYE) Q3 Earnings Top Estimates, Margins Fall

National Vision's (EYE) higher SG&A expenses in the third quarter reflect increases in performance-based incentives and stock-based compensations.

Analysts Estimate National Vision (EYE) to Report a Decline in Earnings: What to Look Out for

National Vision (EYE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Is National Vision (EYE) Stock Undervalued Right Now?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

EYE vs. PODD: Which Stock Is the Better Value Option?

EYE vs. PODD: Which Stock Is the Better Value Option?

Here's Why You Should Retain National Vision (EYE) Stock Now

Investors are optimistic about National Vision's (EYE) stock, banking on comparable store sales growth and stable liquidity.

National Vision (EYE) Gains From Store Opening Amid Macro Woes

In terms of store expansion, National Vision (EYE) continues to see a sizable new opportunity with growth for the coming years.

Is the Options Market Predicting a Spike in National Vision (EYE) Stock?

Investors need to pay close attention to National Vision (EYE) stock based on the movements in the options market lately.

Alcon (ALC) to Report Q2 Earnings: What's in the Cards?

Alcon (ALC) might have benefitted from the high win rate of Argos Biometer in the second quarter.

National Vision (EYE) Q2 Earnings Top Estimates, Margins Down

National Vision's (EYE) second-quarter 2023 performance highlights positive comparable store sales growth, retention and recruitment trends.

National Vision (EYE) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Although the revenue and EPS for National Vision (EYE) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Here's Why You Should Retain National Vision (EYE) Stock Now

Investors are optimistic about National Vision's (EYE) stock, banking on comparable store sales growth and technological investments.

Is a Beat Likely for Cardinal Health (CAH) in Q4 Earnings?

Cardinal Health's (CAH) fiscal fourth-quarter 2023 results are expected to reflect solid performance in the Pharmaceutical segment.

National Vision (EYE) Beats Q2 Earnings and Revenue Estimates

National Vision (EYE) delivered earnings and revenue surprises of 13.33% and 0.03%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

MacroGenics (MGNX) Reports Q2 Loss, Misses Revenue Estimates

MacroGenics (MGNX) delivered earnings and revenue surprises of 30.77% and 51.46%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Why Earnings Season Could Be Great for National Vision (EYE)

National Vision (EYE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

National Vision (EYE) Gains From Store Openings Amid Cost Woes

National Vision (EYE) continues to roll out its remote care capabilities, which provide doctors with additional levels of flexibility and expand exam capacity in many areas.

Urmimala Biswas headshot

3 MedTech Stocks Likely to Top Estimates This Earnings Season

MedTech companies' results are likely to reflect base business recovery on a year-over-year basis. Let's see how EYE, CAH and HSIC are poised ahead of their earnings releases.

Chimerix (CMRX) Reports Q2 Loss, Misses Revenue Estimates

Chimerix (CMRX) delivered earnings and revenue surprises of 8.70% and 95.91%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Here's Why You Should Retain National Vision (EYE) Stock Now

Investors continue to remain optimistic about National Vision (EYE) due to the expansion of stores and new investments for the improved optometric experience.

National Vision (EYE) Plans to Open New Stores Amid Macro Woes

National Vision (EYE) plans to continue executing core growth initiatives and further investing in competitive advantages.

National Vision (EYE) Q1 Earnings Top Estimates, Margins Down

National Vision's (EYE) Q1 net revenues are positively impacted by the timing of unearned revenue.

National Vision (EYE) Q1 Earnings and Revenues Beat Estimates

National Vision (EYE) delivered earnings and revenue surprises of 63.16% and 1.99%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

NuVasive (NUVA) Tops Q1 Earnings and Revenue Estimates

NuVasive (NUVA) delivered earnings and revenue surprises of 14.63% and 3.11%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Is a Surprise Coming for National Vision (EYE) This Earnings Season?

National Vision (EYE) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Analysts Estimate National Vision (EYE) to Report a Decline in Earnings: What to Look Out for

National Vision (EYE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.